Alivus Life Sciences Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹17,150 Cr
- P/E
- 27.59
- ROE
- 17.88%
- PEG
- 4.95
- Price to sales
- 6.61
- Debt to equity
- 0.02
- 52W high / low
- ₹1,444 / ₹860
- Sales growth (5Y)
- 6.24%
- EBITDA margin
- 32.30%
- Net profit margin
- 21.54%
- Promoter holding
- 74.85%
- Sales (last year)
- ₹2,590 Cr
Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
Guidance scorecard · Q2 FY27 call
What Alivus Life Sciences Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
10–20%- Alivus Life Sciences expects revenue growth of 10% to 12% in FY '27, with stronger growth skewed towards the second half of the year.
- Non-GPL business is driving strong growth, with a 26.5% year-on-year increase in Q1 FY '27, supported by a robust product pipeline and recent launches.
- CDMO business is anticipated to accelerate in H2 FY '27 and beyond as new projects commercialize, contributing to faster growth than the overall business.
- The company is working on 7 active CDMO projects and anticipates closing 2 new CDMO contracts in early H2 FY '27.
- Pipeline of 28-29 new high-potent API products being commercialized gradually, with significant launches expected from FY '28 onward.
2 more points from Alivus Life Sciences Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
Up 0–2%See what Alivus Life Sciences Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Capex for Q1 FY '27 was INR85 crores; expected capex for FY '27 is approximately INR540 crores.
- Priority capex focus remains on completion of expansions at Dahej (160KL increase) and Ankleshwar (110KL increase), both on track.
- Solapur Phase 1 and 1.1 nearing completion, to be operational by Q3 FY '27, with inspections planned within a year post-operation for regulatory approvals.
- Solapur expansion (Phase 3) has been delayed by about a year to avoid under-absorption and is planned as a greenfield project.
- New R&D center construction at Taloja has begun and is progressing on schedule.
- Investment focus on new API launches and improving manufacturing capabilities, especially for regulated markets.
2 more points from Alivus Life Sciences Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Alivus Life Sciences Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
Rising- Alivus Life Sciences is actively engaged in about 7 ongoing CDMO projects.
- Revenue currently comes from 5 existing projects.
- There are new inquiries beyond these 7 projects, indicating a steady flow of potential business.
- The CDMO segment is expected to accelerate growth in H2 FY '27 and continue expanding in FY '28 with new projects kicking in.
- The company is confident of maintaining steady demand and growth from its existing pipeline and new launches.
- The robust product pipeline includes 29 active high-potent API products with a total addressable market of $82 billion.
2 more points from Alivus Life Sciences Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Alivus Life Sciences Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Alivus Life Sciences Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Alivus Life Sciences Ltd
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 82.85% | 82.85% | 82.85% | 75.00% | 75.00% | 74.99% | 74.94% | 74.91% | 74.91% | 74.87% | 74.87% | 74.85% |
| FIIs + | 4.57% | 5.01% | 4.81% | 7.85% | 6.74% | 6.57% | 6.42% | 6.84% | 5.08% | 5.30% | 5.54% | 5.93% |
| DIIs + | 0.74% | 1.41% | 1.57% | 4.16% | 4.86% | 5.19% | 5.62% | 5.47% | 7.13% | 7.27% | 7.18% | 7.03% |
| Public + | 11.84% | 10.73% | 10.76% | 12.99% | 13.40% | 13.25% | 13.03% | 12.79% | 12.89% | 12.55% | 12.42% | 12.19% |
| No. of Shareholders | 1,85,531 | 1,56,183 | 1,49,396 | 1,43,960 | 1,46,840 | 1,41,977 | 1,38,500 | 1,35,643 | 1,32,748 | 1,27,969 | 1,25,559 | 1,22,777 |
Financials of Alivus Life Sciences Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 578 | 595 | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 |
| Expenses + | 385 | 428 | 400 | 395 | 429 | 373 | 452 | 451 | 430 | 409 | 442 | 475 | 429 |
| Operating Profit | 193 | 167 | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 | 212 |
| OPM % | 33% | 28% | 30% | 26% | 27% | 27% | 30% | 31% | 29% | 30% | 34% | 31% | 33% |
| Other Income + | 2 | 5 | 2 | 3 | 5 | 9 | 10 | 10 | 9 | 15 | -12 | 23 | 22 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 13 | 13 | 13 | 15 | 14 | 15 | 15 | 16 | 17 | 18 | 20 | 20 | 21 |
| Profit before tax | 182 | 159 | 161 | 130 | 150 | 127 | 185 | 191 | 163 | 174 | 198 | 216 | 212 |
| Tax % | 26% | 25% | 26% | 24% | 26% | 25% | 26% | 26% | 25% | 25% | 24% | 25% | 25% |
| Net Profit + | 135 | 119 | 119 | 98 | 111 | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 |
| EPS in Rs | 11.05 | 9.69 | 9.69 | 7.99 | 9.10 | 7.78 | 11.18 | 11.58 | 9.91 | 10.60 | 12.25 | 13.25 | 13.04 |
Financials of Alivus Life Sciences Ltd
Profit & Loss
Annual income statement trend
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0 | 886 | 1,537 | 1,885 | 2,123 | 2,161 | 2,283 | 2,387 | 2,552 | 2,590 |
| Expenses + | 0 | 638 | 1,064 | 1,294 | 1,506 | 1,518 | 1,608 | 1,702 | 1,754 | 1,754 |
| Operating Profit | -0 | 248 | 473 | 592 | 617 | 643 | 675 | 684 | 798 | 837 |
| OPM % | -4.0% | 28% | 31% | 31% | 29% | 30% | 30% | 29% | 31% | 32% |
| Other Income + | 0 | -0 | 11 | 0 | 14 | 28 | 11 | 33 | 34 | 48 |
| Interest | 0 | 1 | 34 | 88 | 28 | 1 | 2 | 2 | 5 | 5 |
| Depreciation | 0 | 19 | 29 | 33 | 38 | 42 | 53 | 61 | 75 | 79 |
| Profit before tax | -0 | 228 | 421 | 471 | 565 | 629 | 631 | 654 | 751 | 801 |
| Tax % | 4,200% | 14% | 26% | 25% | 26% | 26% | 25% | 26% | 25% | |
| Net Profit + | -0 | 196 | 313 | 352 | 419 | 467 | 471 | 486 | 564 | 603 |
| EPS in Rs | -3.91 | 18.14 | 29.04 | 32.61 | 34.17 | 38.11 | 38.43 | 39.63 | 45.99 | 49.14 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 61% | 110% | 59% | 13% | 11% |
Financials of Alivus Life Sciences Ltd
Balance Sheet
Capital structure and asset base
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 2 | 2 | 2 | 25 | 25 | 25 | 25 | 25 |
| Reserves | -1 | 86 | 400 | 751 | 2,030 | 2,114 | 2,308 | 2,793 | 3,308 |
| Borrowings + | 0 | 0 | 0 | 0 | 3 | 19 | 17 | 57 | 57 |
| Other Liabilities + | 1 | 1,387 | 1,324 | 1,244 | 414 | 545 | 501 | 537 | 594 |
| Total Liabilities | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 | 3,983 |
| Fixed Assets + | 0 | 456 | 546 | 573 | 595 | 781 | 805 | 955 | 1,038 |
| CWIP | 0 | 80 | 11 | 14 | 92 | 62 | 106 | 102 | 284 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 478 | 780 |
| Other Assets + | 0 | 939 | 1,169 | 1,410 | 1,784 | 1,860 | 1,939 | 1,877 | 1,881 |
| Total Assets | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 | 3,983 |
Financials of Alivus Life Sciences Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -0 | 10 | 195 | 388 | 598 | 306 | 414 | 392 | 565 |
| Cash from Investing Activity + | 0 | -9 | -51 | -69 | -122 | -147 | -116 | -616 | -570 |
| Cash from Financing Activity + | 0 | 1 | -137 | -214 | -79 | -388 | -279 | -6 | -64 |
| Net Cash Flow | 0 | 2 | 8 | 106 | 397 | -228 | 18 | -230 | -69 |
| Free Cash Flow | -0 | 1 | 144 | 322 | 466 | 143 | 285 | 226 | 259 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 4,800% | 14% | 61% | 84% | 119% | 71% | 85% | 81% | 93% |
Financials of Alivus Life Sciences Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 44 | 185 | 152 | 120 | 116 | 136 | 122 | 148 | 153 |
| Inventory Days | 162 | 441 | 227 | 214 | 185 | 224 | 251 | 237 | 246 |
| Days Payable | 41 | 201 | 111 | 92 | 110 | 158 | 139 | 137 | 132 |
| Cash Conversion Cycle | 165 | 424 | 268 | 241 | 190 | 202 | 235 | 248 | 267 |
| Working Capital Days | -2,059 | -186 | -37 | 12 | 149 | 176 | 188 | 201 | 194 |
| ROCE % | 529% | 186% | 97% | 42% | 30% | 28% | 25% | 24% |
Guidance history
How Alivus Life Sciences Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Up 0–2% | Planned | — | Rising |
| Q4 FY26 call → | 0–10% | Flat | Planned | — | — |
| Q3 FY26 call → | 0–10% | Up 2%+ | Planned | — | — |
| Q2 FY26 call → | 0–10% | Flat | Planned | — | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
85 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +53.9% | 86% |
| Last 6 months | +34.6% | 83% |
| Last 3 months | +27.5% | 90% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Alivus Life Sciences Ltd: 0.4 × 86 + 0.4 × 83 + 0.2 × 90 = 85.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Alivus Life Sciences Ltd's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY
- Aarti Pharmalabs Ltd (Q2 FY27)
19,211.62 lakhs (~45.9% increase) . Key investor presentation takeaways from Aarti Pharmalabs Ltd's Q2 FY27 investor presentation — and how it ranks against sec